Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease - Pfizer ( NYSE:PFE )
Inclacumab fails to reduce VOC rates in sickle cell patients in Phase 3 trial. Pfizer will continue developing its broader sickle cell portfolio. Get the latest proven ETF strategies to target and profit from summer volatility before the next big market swing. Pfizer Inc.
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?
CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark
Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. The company provides updates on pipeline progress.
Beam Therapeutics Inc. ( BEAM ) Reports Q2 Loss, Misses Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of +3.85% and -38.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
WALTHAM, Mass., July 31, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) , today announced its second quarter 2025 financial results and business highlights.
Vir Biotechnology, Inc. ( VIR ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Vir Biotechnology (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech ...
Will Beam Therapeutics Inc. ( BEAM ) Report Negative Q2 Earnings? What You Should Know
Beam Therapeutics (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beam Therapeutics ( BEAM ) Surges 5.7%: Is This an Indication of Further Gains?
Beam Therapeutics (BEAM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Innovation ETF ( ARKK ) Hits New 52-Week High
Cathie Wood's ARKK hits a 52-week high after bold biotech moves, signaling renewed momentum in disruptive tech.
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global ...
3 Promising Genomics Stocks to Keep an Eye On in 2025
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
Cathie Wood Doubles Down On Shopify, Buys The Dip - Dumps $4.6 Million Worth Of Robinhood Stock At Peak - ARK Fintech Innovation ETF ( BATS:ARKF ) , ARK Innovation ETF ( BATS:ARKK )
Cathie Wood-led Ark Invest made notable trades on Wednesday, focusing on Shopify Inc. SHOP and Robinhood Markets Inc. HOOD.
Cathie Wood Drops $6.5 Million On SHOP And ABNB, Betting You Won't Stop Shopping Or Traveling - ARK Fintech Innovation ETF ( BATS:ARKF ) , Airbnb ( NASDAQ:ABNB )
Cathie Wood-led Ark Invest made significant trades on Tuesday, spotlighting its strategic acquisitions of Shopify Inc. SHOP and Airbnb Inc. ABNB. These trades reflect Ark's continued interest in high-growth technology and e-commerce sectors.
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?
CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Eli Lilly ( NYSE:LLY ) , Verve Therapeutics ( NASDAQ:VERV )
Eli Lilly offered a 115% premium for Verve, signaling a major vote of confidence in gene editing platforms. HC Wainwright and William Blair downgraded Verve after the deal. Last Chance: See the "Power Pattern" That Delivered Winners 9 Out of the Last 10 Summers. Get The Details Here
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
The biotechnology sector is a thrilling arena for investors, with a history of delivering groundbreaking medical innovations that have led to massive shareholder returns. Editas Medicine ( NASDAQ: EDIT ) is a promising clinical-stage company that has captured Wall Street's attention at the ...
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease ( SCD ) at European Hematology Association ( EHA ) 2025 Congress
Updated Data from 17 Patients Consistent with Previously Presented Data. All Patients Treated with BEAM-101 Achieved Hemoglobin F ( HbF ) Induction of >60%, Hemoglobin S ( HbS ) Reduction to <40%, and Resolution of Anemia ...
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
Beam Therapeutics ( BEAM ) Up 5.7% Since Last Earnings Report: Can It Continue?
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?
CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease - Beam Therapeutics ( NASDAQ:BEAM )
CAMBRIDGE, Mass., June 03, 2025 ( GLOBE NEWSWIRE ) -- Beam Therapeutics Inc.
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency ( AATD ) - Beam Therapeutics ( NASDAQ:BEAM )
CAMBRIDGE, Mass., May 29, 2025 ( GLOBE NEWSWIRE ) -- Beam Therapeutics Inc.
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
BMRN and NVAX are in the spotlight this week following announcement agreement and regulatory update.
3 Top Genomics Stocks to Add to Your Portfolio in 2025
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively.
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition - Prime Medicine ( NASDAQ:PRME )
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively.
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association ( EHA ) 2025 Congress
Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of ...
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference - Beam Therapeutics ( NASDAQ:BEAM )
CAMBRIDGE, Mass., May 13, 2025 ( GLOBE NEWSWIRE ) -- Beam Therapeutics Inc. BEAM, a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference ...
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging
Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates
INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up
NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates
PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up
Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut
IOVA reports dismal first-quarter results. The share price plunges after the company significantly lowers its 2025 sales guidance.
Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains
VTRS Q1 earnings and sales beat estimates. Brands business continues to perform well backed by expansion of portfolio.
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised
MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance. Shares rise.
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y
AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates
Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.
Why Beam Therapeutics Stock Tanked on Tuesday
Precision gene-editing company Beam Therapeutics ( NASDAQ: BEAM ) had a Tuesday to forget on the stock market. Following the release that morning of its latest set of quarterly results, the shares raced downwards to a more than 19% loss on the day.
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down
KRYS reports disappointing first-quarter 2025 results, with both earnings and sales missing estimates. Shares down.
Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised
ZTS reports better-than-expected first-quarter results as earnings and revenues surpass estimates. Management raises 2025 guidance.
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates
Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of certain key pipeline programs.
Beam Therapeutics Inc. ( BEAM ) Reports Q1 Loss, Misses Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -11.71% and 51.29%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
